The Obama administration says the number of Medicare patients returning to hospitals within 30 days fell further in 2013, amounting to 150,000 fewer readmissions since January 2012.
The Obama administration says the number of Medicare patients returning to hospitals within 30 days fell further in 2013, amounting to 150,000 fewer readmissions since January 2012.
HHS describes the progress on readmissions in a brief report out Wednesday that claims the administration's quality initiatives and partnerships have achieved significant successes, including a reduction in hospital-induced harms credited with saving 15,000 lives and $4 billion.
The all-cause readmissions rate, according to the report, has declined to 17.5% in the past two years after hovering between 19% and 19.5% since 2007. Under the Patient Protection and Affordable Care Act, hospitals' Medicare payments are docked for high rates of readmissions. The penalty rises to 3% in fiscal 2015.
Read the full story here: http://bit.ly/1s2VLPk
Source: Modern Healthcare
Examining Telehealth Uptake to Increase Equitable Care Access
January 26th 2023To mark the publication of The American Journal of Managed Care®’s 12th annual health IT issue, on this episode of Managed Care Cast, we speak with Christopher M. Whaley, PhD, health care economist at the RAND Corporation, who focuses on health economics issues, including the influence of the COVID-19 pandemic on health care delivery.
Listen
High-Deductible Health Plans and Their Potential Impact on the US Drug Epidemic
October 13th 2022On this episode of Managed Care Cast, we speak with Matthew D. Eisenberg, PhD, lead author of a study published in the October issue of The American Journal of Managed Care® that investigated the use of high-deductible health plans and their impact on substance use disorder care and spending.
Listen
FDA Approves Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
January 28th 2023The FDA has approved pirtobrutinib (Jaypirca) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma following at least 2 lines of systemic therapy, including a previous Bruton tyrosine kinase (BTK) inhibitor.
Read More
FDA Approves Elacestrant for ER+/HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer
January 27th 2023The FDA has approved elacestrant (Orserdu) for the treatment of postmenopausal women or adult men with estrogen receptor–positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least 1 line of endocrine therapy.
Read More
2 Clarke Drive
Cranbury, NJ 08512